ALXN2230

ALXN2230 is an investigational monoclonal antibody developed by Alexion Pharmaceuticals (the rare disease unit of AstraZeneca) that targets the neonatal Fc receptor (FcRn). By binding to FcRn, ALXN2230 blocks the recycling pathway of immunoglobulin G (IgG), leading to the rapid clearance and reduction of circulating IgG levels, including pathogenic autoantibodies. This mechanism is designed to treat a variety of IgG-mediated autoimmune conditions, such as generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), where autoantibodies cause tissue damage and neuromuscular dysfunction. ALXN2230 is currently being evaluated in Phase 1 clinical trials to assess its safety, pharmacokinetics, and pharmacodynamics, with a focus on subcutaneous administration.